Miglustat Oral Capsule [Zavesca]
RxNorm 541069

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 541069 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: miglustat Oral Capsule [Zavesca].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDF
Miglustat Oral Capsule [Zavesca]
AUI:12313489
View
TMSY
MigLUstat Oral Capsule [Zavesca]
AUI:12814826
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDFPrescribable

Semantic Branded Drug Form (SBDF):
Miglustat Oral Capsule [Zavesca]
(Atom ID: 12313489)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
miglustat Oral Capsule [Zavesca]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
541069
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12313489
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDF
Semantic Branded Drug Form (Ingredient + Dose Form + Brand Name)
Source Code
541069
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
TMSYPrescribable

Tall Man Lettering Synonym (TMSY):
MigLUstat Oral Capsule [Zavesca]
(Atom ID: 12814826)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
migLUstat Oral Capsule [Zavesca]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
541069
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12814826
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
541069
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Miglustat


Miglustat is used to treat Gaucher disease type 1 (a condition in which a certain fatty substance is not broken down normally in the body and instead builds up in some organs and causes liver, spleen, bone, and blood problems). Miglustat is in a class of medications called enzyme inhibitors. It works by preventing the body from producing the fatty substance so that less of it will build up in the body and cause symptoms.
[Learn More]


* Please review the disclaimer below.